ClinicalTrials.gg
RecruitingNCT06640413TheraTriUpdated Oct 26, 2026

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

A Phase 1 interventional study of [177Lu]Lu-OncoFAP-23 and L19IL2 in FAP, sponsored by Philogen S.p.A.. Recruiting at 4 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to assess the safety of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic Fibroblast Activation Protein (FAP)-positive solid tumors and to establish a Recommended Dose (RD).

Read the detailed description

This study is a prospective phase I, open-label, multiple ascending, multi-center dose escalation study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with the antibody-cytokine conjugate L19-IL2 for the treatment of advanced/metastatic FAP-positive solid tumors.

Eligible patients for this trial are male or non-pregnant and non-breastfeeding females aged 18 years or more, able to give informed consent.

Up to 56 evaluable patients will be enrolled in the trial and the trial is divided into two parts:

  1. Part I - Dose escalation part (2-36 pts) This dose escalation part of the study is designed as a standard 3+3 escalation scheme. Not more than 2 patients per cohort are treated simultaneously during the Dose Limiting Toxicity (DLT) observation period from Day 1 to Day 28 of the first cycle. Patients per cohort will be assigned to different dose levels of the study drug.
  2. Part II - Dose expansion part (20 pts) After completion of the dose escalation part, additional 20 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications. Patients will be randomly assigned to arm 1 (monotherapy) or arm 2 (combination therapy) (10 patients each).

Both in part I and II, patients can receive up to 4 consecutive cycles of radioligand therapy every 8 (± 1) weeks.

The primary objective of this study is to assess the safety of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic FAP-positive malignancies and to establish a Recommended Dose (RD).

Secondary objectives include evaluation of pharmacokinetics and the collection of initial signs of efficacy of the treatment.

02

Conditions studied

  • FAP

Keywords

  • Patients with advanced/metastatic FAP-positive tumors
03

In context

Lead sponsor

Philogen S.p.A. is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with advanced/ solid tumors, who have progressed on available standard treatments.
  2. Patients with FAP-positive tumors as evaluated by [68Ga]Ga-OncoFAP-DOTAGA-PET/CT imaging.
  3. Patients without other therapeutic alternatives with curative or survival prolonging potential as per investigator judgement.
  4. Male or non-pregnant and non-breast feeding female, age 18 or more.
  5. Patients must have at least one unidimensionally by computed tomography as defined by criteria 1.1. This lesion should not have been irradiated during previous treatments.
  6. (ECOG) performance status ≤ 2.
  7. Survival expectation of more than 12 weeks.
  8. Ability to undergo standard imaging.
  9. Documented negative test for (HIV), Virus (HBV) and Virus (HCV). For HBV serology: the determination of HBsAg and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBsAg-Ab with no history of vaccination and/or anti-HBcAg-Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  10. All acute toxic effects (excluding alopecia and fatigue) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) (CTCAE) (v. 5.0) Grade ≤ 1.
  11. Female patients: negative blood pregnancy test at Screening for women of (WOCBP)*. WOCBP must agree to use, from the screening to six months following the last study drug administration, highly effective methods, as defined by the Recommendations for contraception and pregnancy testing in clinical ; issued by the Head of Medicine Agencies; Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.
  12. Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g., condom with spermicidal gel). Double-barrier contraception is required.
  13. A personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study and has given consent to participate in the study.
  14. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Women of childbearing potential are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria:

  1. Any cancer therapy within 4 weeks of study entry.
  2. Active or history of disease that might deteriorate when receiving an immuno-stimulatory agent.
  3. Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, Iodine-131, Lutetium-177 conjugates or hemi-body irradiation within 6 months prior to enrollment.
  4. White blood cell count (WBC) minor than 2.5 x 109/L, (ANC) minor than 1.5 x 109/L, minor than 100 x 109/L or (Hb) minor than 9.0 g/dl,
  5. Chronically impaired renal function as expressed by minor than 60 mL/min or serum creatinine major than 1.5 .
  6. Inadequate liver function ( (ALT) or Aspartate Aminotransferase (AST) ≥ 3 x Upper Limit of Normal (ULN), or Alkaline Phosphatase (ALP) or Gamma Glutamyl Transferase (GGT) ≥ 2.5 x ULN, or total ≥ 1.5 x ULN). For patients with lesions in the liver ALT, AST, GGT or ALP ≥ 5 x ULN.
  7. Presence of cirrhosis or active hepatitis.
  8. Patients with Central Nervous System (CNS) metastases.
  9. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  10. Heart insufficiency (major Grade II, (NYHA) criteria).
  11. cardiac arrhythmias or requiring permanent medication.
  12. Abnormal (LVEF) or any other abnormalities observed during baseline (ECG) and echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current, or a history of /QTc prolongation would be excluded. In particular: - patients with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of QTc major than 480 milliseconds using Fredricia's QT correction formula) are excluded; - patients with a history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of prolonged QT syndrome) are excluded; - patients who require the use of concomitant medications that prolong the QT/QTc interval are excluded.
  13. Cardioversion in the previous 12 months
  14. Uncontrolled hypertension as defined by systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg at 3 consecutive measurements performed within one week. Note: if the first blood pressure measurement is below threshold for systolic or diastolic blood pressure, it is not required to repeat the measurement.
  15. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  16. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  17. Pregnancy or lactation or unwillingness to use adequate method of .
  18. Any severe concomitant condition which in the opinion of investigators makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  19. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of the study drug.
  20. Serious, non-healing wound, ulcer or bone fracture.
  21. Known history of allergy to an in study medication or any other intravenously administered human proteins/peptides/antibodies
  22. Systemic chronic therapy (major than 10 mg/day prednisone or equivalent) or any other therapy within 14 days prior to study treatment start. Topical, inhaled, nasal and ophthalmic steroids are allowed.
  23. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  24. Concurrent or previous (other than the indication for this trial), unless a complete remission without further recurrence was achieved at least 2 years prior to study treatment start.
  25. Growth factors or immunomodulatory agents within 7 days prior to study treatment start.
  26. Deep vein thrombosis, pulmonary embolism, or other acute vascular events within 6 months.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Part I - Dose Escalation - Cohort 1, Arm 1

    In Arm 1, patients assigned to this cohort 1, receive monotherapy of \[177Lu\]Lu-OncoFAP-23 (3.7 GBq)

    Drug: [177Lu]Lu-OncoFAP-23

  • Experimental
    Part I - Dose Escalation - Cohort 2, Arm 1

    In Arm 1, patients assigned to this cohort 2, receive monotherapy of \[177Lu\]Lu-OncoFAP-23 (7.4 GBq)

    Drug: [177Lu]Lu-OncoFAP-23

  • Experimental
    Part I - Dose Escalation - Cohort 3, Arm 1

    In Arm 1, patients assigned to this cohort 3, receive monotherapy of \[177Lu\]Lu-OncoFAP-23 (11.1 GBq)

    Drug: [177Lu]Lu-OncoFAP-23

  • Experimental
    Part I - Dose Escalation - Cohort 4, Arm 2

    In Arm 2, patients assigned to this cohort 4, receive combination of \[177Lu\]Lu-OncoFAP-23 at at the dose level below the Maximum Tolerated Dose (MTD) with L19IL2 (22.5 Mio IU).

    Drug: [177Lu]Lu-OncoFAP-23 · Drug: L19IL2

  • Experimental
    Part I - Dose Escalation - Cohort 5, Arm 2

    In Arm 2, patients assigned to this cohort 4, receive combination of \[177Lu\]Lu-OncoFAP-23 at MTD with L19IL2 (22.5 Mio IU).

    Drug: [177Lu]Lu-OncoFAP-23 · Drug: L19IL2

  • Experimental
    Part II - Dose Expansion - Arm 1

    10 patients receive the monotherapy of \[177Lu\]Lu-OncoFAP-23 at the recommended dose

    Drug: [177Lu]Lu-OncoFAP-23

  • Experimental
    Part II - Dose Expansion - Arm 2

    10 patients receive the combination of \[177Lu\]Lu-OncoFAP-23 and L19IL2 at the recommended doses

    Drug: [177Lu]Lu-OncoFAP-23 · Drug: L19IL2

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    Dose Limiting Toxicity (DLT)

    Time frame: From Day 1 to 28 of the dose escalation part

  2. Maximum Tolerated Dose (MTD) and Recommended Dose (RD)

    Maximum Tolerated Dose (MTD) and Recommended Dose (RD)

    Time frame: From Day 1 to 28 of the dose escalation part

  3. Maximum Administered Dose (MAD)

    Maximum Administered Dose (MAD)

    Time frame: From Day 1 to 28 of the dose escalation part

  4. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Adverse events (AEs) and Serious Adverse Events (SAEs) assessment based on Common Terminology Criteria for Adverse Events v. 5.0 (CTCAE)

    Time frame: through study completion, maximum 1 year

  5. Drug Induced Liver Injury (DILI)

    Drug Induced Liver Injury (DILI) assessment based on Common Terminology Criteria for Adverse Events v. 5.0 (CTCAE)

    Time frame: through study completion, maximum 1 year

07

Study locations

2 of 4 sites recruiting
  • ASST Papa Giovanni XXIII Piazza OMS
    Bergamo, Bergamo 24127, Italy
    Recruiting
    • Paola Anna Erba, Prof MD PhD · Contactpaolaanna.erba@unimib.it · +390352674642
    • Paola Anna Erba, Prof MD PhD · Principal investigator
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Milano 20133, Italy
    Recruiting
  • Istituto Europeo di Oncologia
    Milan, Milano 20141, Italy
    Not yet recruiting
    • Giuseppe Curigliano, MD PhD · ContactGiuseppe.curigliano@ieo.it · +390257489960
    • Giuseppe Curigliano, MD PhD · Principal investigator
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Via Mariano Semmola
    Naples, Napoli 80131, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for May 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 15, 2024
StartActual
Oct 31, 2025
Primary completionEst.
May 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Via Mariano Semmola · Naples, ItalyContact s•••@istitutotumori.na.it · •••0544→f•••@istitutotumori.na.it · •••0329Contact person changed (no phone or email listed)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Via Mariano Semmola · Naples, ItalyContact s•••@istitutotumori.na.it · •••0544→f•••@istitutotumori.na.it · •••0329Contact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06640413
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 31, 2025
Primary completion
May 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Jacqueline Mock, PhD
Contact
regulatory@philogen.com
+41435448802
Federica Bastioli, Pharmaceutical Chemist
Contact
regulatory@philogen.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion